PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPY

In the last decade, molecularly-targeted therapy is the most intensively developing treatment modalities in oncology. The main targets for this therapy are many elements of apoptosis signaling pathways and cell cycle regulation, the damage of which is associated with a malignant growth. One of the available molecular targets is the epidermal growth factor receptor (EGFR), which activation occurs in lung cancer, colorectal cancer, squamous cell carcinoma of the head and neck , breast cancer, melanomas, etc. To block oncogenic EGFR signaling, target drug as small molecule tyrosine kinase inhibitors, peptide associated cytotoxins and antiEGFR monoclonal antibodies were created. However, there are a number of studies (FLEX, SATURN, INTEREST, IPASS), where the expected and observed clinical cure rates of target drugs are not the same, including primary goal - increasing time to tumor progression. As the cause of inconsistency of treatment results may be lack the selection of patients with the additional molecular damages (mutations or genetic polymorphisms), providing the sensitivity and /or resistance to therapeutic agent. The most important reason for discrepancy between the real and the expected treatment effect of target drugs is the phenomenon of intratumoral heterogeneity, that is manifested as coexist of cells with different biological properties, due to genetic, epigenetic, phenotypic peculiarities of tumor clones within the tumor. Search for new driver targets and the creation of drugs directed against them, development of multitarget approach are perspective to improve the effectiveness of targeted therapy. In addition, it is important to use molecular testing to monitor the treatment efficacy, because therapy can drive the tumor clonal evolution, leading to the emergence of resistant cell clones.

1. Artamonova E.V. New possibilities of treatment of locally advanced rectal cancer // Sovremennaja onkologija. 2011. Vol. 13 (3). P. 29–34. [in Russian]

2. Borisova E.I., Gutorov S.L. Rational drug therapy of non-small cell lung cancer // Sovremennaja onkologija. 2011. Vol. 13 (3). P. 45–50. [in Russian]

3. Gerashhenko T.S., Denisov E.V., Litvjakov N.V., Zav’jalova M.V., Vtorushin S.V., Cyganov M.M., Perel’muter V.M., Cherdynceva N.V. Intratumoral Heterogeneity: Nature and Biological Significance (review) // Biohimija. 2013. Vol. 78 (11). P. 1531–1549. [in Russian]

4. Imjanitov E.N. Клинико-молекулярные аспекты колоректального рака: этиопатогенез, профилактика, индивидуализация лечения // Prakticheskaja onkologija. 2005. Vol. 6 (2). P. 65–68. [in Russian]

5. Imjanitov E.N. Молекулярная патология рака легкого: клинические аспекты // Prakticheskaja onkologija. 2006. Vol. 7 (3). P. 131–137. [in Russian]

6. Moiseenko F.V., Imjanitov E.N., Macko D.E., Semenov I.I., Levchenko E.V., Moiseenko V.M., Procenko C.A., Chubenko V.A., Brezhnev N.V., Ievleva A.G., Ivancov A.O., Abduloeva N.H. The role of gefitinib in the treatment of inoperable NSCLC carrying EGFR-mutation // Sovremennaja onkologija. 2011. Vol. 13 (3). P. 50–55. [in Russian]

7. Nosov D.A. Таргетная терапия при диссеминированном раке почки: успехи и перспективы // Prakticheskaja onkologija. 2010. Vol. 11 (3). P. 171–181. [in Russian]

8. Perel’muter V.M., Zav’jalova M.V., Vtorushin S.V., Slonimskaja E.M., Savenkova O.V. Interraction between morphologic heterogeneity of infiltrating ductal breast carcinoma and various forms of tumor progression // Sibirskij onkologicheskij zhurnal. 2007. № 3. P. 58–63. [in Russian]

9. Poljakov I.S., Imjanitov E.N. Molecular pathology of lung cancer: clinical aspects // Sibirskij onkologicheskij zhurnal. 2013. № 6. P. 48–55. [in Russian]

10. Procenko S.A. Таргетная терапия при меланоме, гастроинтестинальных стромальных опухолях, дерматофибросаркоме протуберанс // Prakticheskaja onkologija. 2010. Vol. 11 (3). P. 162–170. [in Russian]

11. Snegovoj A.V., Manzjuk L.V. Значение биомаркеров для определения тактики лечения и прогноза злокачественных опухолей // Prakticheskaja onkologija. 2011. Vol. 12 (4). P. 166–170. [in Russian]

12. Tjuljandin S.A. Первые результаты клинического применения ингибиторов передачи внутриклеточных сигналов // Prakticheskaja onkologija. 2010. № 11 (3). С. 236–245. [in Russian]

13. Trjakin A.A. Таргетная терапия колоректального рака, рака желудка и поджелудочной железы // Prakticheskaja onkologija. 2010. Vol. 11 (3). P. 143–150. [in Russian]

14. Bedard P.L., Hansen A.R., Ratain M.J., Siu L.L. Tumour heterogeneity in the clinic // Nature. 2013. 501 (7467). P. 355–364. doi: 10.1038/nature12627.

15. Bhatia S., Frangioni J.V., Hoffman R.M., Iafrate A.J., Polyak K. The challenges posed by cancer heterogeneity // Nat. Biotechnol. 2012. Vol. 30. P. 604–610. doi: 10.1038/nbt.2294

16. Cherdyntseva N.V., Gervas P.A., Litvyakov N.V., Stakcheeva M.N., Ponomaryeva A.A., Dobrodeev A.Y., Denisov E.V., Belyavskaya V.A., Choinzonov E.L. Age-related function of tumor suppressor gene tp53: contribution to cancer risk and progression // Exp. Oncol. 2010. Vol. 32 (3). P. 205–208.

17. De Roock W., Jonker D.J., Di Nicolantonio F., SartoreBianchi A., Tu D., Siena S., Lamba .S, Arena S., Frattini M., Piessevaux H., Van Cutsem E., O’Callaghan C.J., Khambata-Ford S., Zalcberg J.R., Simes J., Karapetis C.S., Bardelli A., Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapyrefractory metastatic colorectal cancer treated with cetuximab // JAMA. 2010. Vol. 304 (16). P.1812–1820. doi: 10.1001/jama.2010.1535.

18. Duffy M.J., Crown J. Precision treatment for cancer: role of prognostic and predictive markers // Crit. Rev. Clin. Lab. Sci. 2014. Vol. 51 (1). P. 30–45. doi: 10.3109/10408363.2013.865700.

19. Ebos J.M., Lee C.R., Kerbel R.S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy // Clin. Cancer Res. 2009. Vol. 15 (16). P. 5020–5025. doi: 10.1158/1078-0432.CCR-09-0095.

20. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy // Clin. Cancer Res. 2008. Vol. 14 (20). P. 6371–6375. doi: 10.1158/1078-0432.CCR-07-5287.

21. Fisher R., Pusztai L., Swanton C. Cancer heterogeneity: implications for targeted therapeutics // Br. J. Cancer. 2013. Vol. 108 (3). P. 479–485. doi: 10.1038/bjc.2012.581.

22. Gold K.A., Wistuba I.I., Kim E.S. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy // Clin. Cancer Res. 2012. Vol. 18 (11). P. 3002–3007. doi: 10.1158/1078-0432.CCR-11-2055.

23. Greaves W.O., Verma S., Patel K.P., Davies M.A., Barkoh B.A., Galbincea J.M., Yao H., Lazar A.J., Aldape K.D., Medeiros L.J., Luthra R. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma // J. Mol. Diagn. 2013. Vol. 15 (2). P. 220–226. doi: 10.1016/j.jmoldx.2012.10.002.

24. Gridelli C., De Marinis F., Di Maio M., Cortinovis D., Cappuzzo F., Mok T. Gefitinib as first-line treatment for patients with advanced nonsmall-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues // Lung Cancer. 2011. Vol. 72 (1). P. 3–8. doi: 10.1016/j.lungcan.2010.12.009

25. Imianitov E.N. Molecular diagnosis in oncology // Mol. Biol. 2008. Vol. 42 (5). P. 772–785.

26. Linardou H., Briasoulis E., Dahabreh I.J., Mountzios G., Papadimitriou C., Papadopoulos S., Bafaloukos D., Kosmidis P., Murray S. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer // Cancer Treat. Rev. 2011. Vol. 37 (3). P. 221–233. doi: 10.1016/j. ctrv.2010.07.008

27. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., Jenkins R.B., Kwiatkowski D.J., Saldivar J.S., Squire J., Thunnissen E., Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology // J. Mol. Diagn. 2013. Vol. 15 (4). P. 415–453. doi: 10.1016/j.jmoldx.2013.03.001.

28. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Morita S., Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR // N. Engl. J. Med. 2010. Vol. Vol. 362 (25). P. 2380–2388. doi: 10.1056/ NEJMoa0909530.

29. Medves S., Demoulin J.B. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies // J. Cell Mol. Med. 2012. Vol. 16 (2). P. 237–248. doi: 10.1111/j.1582-4934.2011.01415.x.

30. Moreau S., Saiag P., Aegerter P., Bosset D., Longvert C., HéliasRodzewicz Z., Marin C., Peschaud F., Chagnon S., Zimmermann U., Clerici T., Emile J.F. Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymph nodes // Ann. Surg. Oncol. 2012. Vol. 19 (13). P. 4314–4321. doi: 10.1245/s10434-012-2457-5

31. Ng K.P., Hillmer A.M., Chuah C.T., Juan W.C., Ko T.K., Teo A.S., Ariyaratne P.N., Takahashi N., Sawada K., Fei Y., Soh S., Lee W.H., Huang J.W., Allen J.C. Jr., Woo X.Y., Nagarajan N., Kumar V., Thalamuthu A., Poh W.T., Ang A.L., Mya H.T., How G.F., Yang L.Y., Koh L.P., Chowbay B., Chang C.T., Nadarajan V.S., Chng W.J., Than H., Lim L.C., Goh Y.T., Zhang S., Poh D., Tan P., Seet J.E., Ang M.K., Chau N.M., Ng Q.S., Tan D.S., Soda M., Isobe K., Nöthen M.M., Wong T.Y., Shahab A., Ruan X., Cacheux-Rataboul V., Sung W.K., Tan E.H., Yatabe Y., Mano H., Soo R.A., Chin T.M., Lim W.T., Ruan Y., Ong S.T. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer // Nat. Med. 2012. Vol. 18. P. 521–528. doi: 10.1038/nm.2713.

32. Oliner K., Douillard J.Y., Siena S. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab plus FOLFOX versus FOLFOX as first-line treatment for metastatic colorectal cancer (mCRC) // ASCO, 2013 (poster discussion): 3511.

33. Pao W. New approaches to targeted therapy in lung cancer // Proc. Am. Thorac. Soc. 2012. Vol. 9 (2). P. 72–73. doi: 10.1513/pats.201112- 054MS.

34. Peeters M., Oliner K.S., Parker A., Siena S., Van Cutsem E., Huang J., Humblet Y., Van Laethem J.L., André T., Wiezorek J., Reese D., Patterson S.D. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer // Clin. Cancer Res. 2013. Vol. 19 (7). P. 1902–1912. doi: 10.1158/1078-0432.CCR-12-1913.

35. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., Porta R., Cobo M., Garrido P., Longo F., Moran T., Insa A., De Marinis F., Corre R., Bover I., Illiano A., Dansin E., de Castro J., Milella M., Reguart N., Altavilla G., Jimenez U., Provencio M., Moreno M.A., Terrasa J., Muñoz-Langa J., Valdivia J., Isla D., Domine M., Molinier O., Mazieres J., Baize N., Garcia-Campelo R., Robinet G., Rodriguez-Abreu D., Lopez-Vivanco G., Gebbia V., Ferrera-Delgado L., Bombaron P., Bernabe R., Bearz A., Artal A., Cortesi E., Rolfo C., Sanchez-Ronco M., Drozdowskyj A., Queralt C., de Aguirre I., Ramirez J.L., Sanchez J.J., Molina M.A., Taron M., Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial // Lancet Oncol. 2012. Vol. 13 (3). P. 239–246. doi: 10.1016/S1470-2045(11)70393-X.

36. Roth A.D., Tejpar S., Delorenzi M., Yan P,, Fiocca R., Klingbiel D., Dietrich D., Biesmans B., Bodoky G., Barone C., Aranda E., Nordlinger B., Cisar L., Labianca R., Cunningham D., Van Cutsem E., Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial // J. Clin. Oncol. 2010. Vol. 28 (3). P. 466–474. doi: 10.1200/ JCO.2009.23.3452.

37. Salomon D.S., Brandt R. Epidermal growth factor related peptides and their receptors in human malignancies // Crit. Rev. Oncol. Hematol. 1995. Vol. 19. P. 183–232.

38. Schwartzberg L.S., Rivera F., Karthaus M. et al. A randomized phase II study of mFOLFOX6 with either panitumumab or bevacizumab as first-line treatment in patients with unresectable wild type (WT) KRAS metastatic colorectal cancer (mCRC) // J. Clin. Oncol. 2013. Vol. 30 (Suppl. 34). P. 446.

39. Soda M., Choi YL., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer // Nature. 2007. Vol. 448 (7153). P. 561–566.

40. Tamkovic S.N., Litviakov N.V., Bryzgunova O.E., Dobrodeev A.Y., Rykova E.Y., Tuzikov S.A., Zav’ialov A.A., Vlassov V.V., Cherdyntseva N.V., Laktionov P.P. Cell-surface-bound circulating DNA as a prognostic factor in lung cancer // Ann. NY Acad. Sci. 2008. Vol. 1137. С. 214–217. doi: 10.1196/annals.1448.042.

41. Tejpar S., Celik I., Schlichting M., Sartorius U., Bokemeyer C., Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab // J. Clin. Oncol. 2012. Vol. 30 (29). P. 3570–3577. doi: 10.1200/JCO.2012.42.2592.

42. Thiel A., Heinonen M., Kantonen J., Gylling A., Lahtinen L., Korhonen M., Kytölä S., Mecklin J.P., Orpana A., Peltomäki P., Ristimäki A. BRAF mutation in sporadic colorectal cancer and Lynch syndrome // Virchows Arch. 2013. Vol. 463 (5). P. 613–621. doi: 10.1007/s00428-013-1470-9.

43. Tie J., Lipton L., Desai J., Gibbs P., Jorissen R.N., Christie M., Drummond K.J., Thomson B.N., Usatoff V., Evans P.M., Pick A.W., Knight S., Carne P.W., Berry R., Polglase A., McMurrick P., Zhao Q., Busam D., Strausberg R.L., Domingo E., Tomlinson I.P., Midgley R., Kerr D., Sieber O.M. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer // Clin. Cancer Res. 2011. Vol. 17 (5). P. 1122–1130. doi: 10.1158/1078-0432.CCR-10-1720.

44. Zhang X., Zhang S., Yang X., Yang J., Zhou Q., Yin L., An S., Lin J., Chen S., Xie Z., Zhu M., Zhang X., Wu Y.L. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression // Mol. Cancer. 2010. Vol. 13 (9). P. 188. doi: 10.1186/1476-4598-9-188.